
|Videos|May 12, 2022
Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma
Author(s)Thomas E. Hutson, DO, PharmD
Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab
2
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
3
Novel Anti-CD5 Therapy Earns FDA RMAT Designation in T-Cell Lymphoma
4
Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC
5
































































































